Trial reportBMC oral health2025
Levels of peripheral CD4 + and CD8 + T cells and glycaemic control level in patients with both type 2 mellitus diabetes and stage III-IV periodontitis: a randomized controlled trial in Chinese population.
Trial report in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThe aim of this randomized controlled trial was to investigate the short-term glycated haemoglobin (HbA1c) level and proportional variation of peripheral T-lymphocytes status after subgingival scaling and root planing (SRP) therapy in patients with type 2 diabetes mellitus(T2DM) and stage III-IV periodontitis in Chinese population.
methodsFifty-one participants diagnosed T2DM and stage III-IV periodontitis were enrolled. Twenty-seven of them were randomly assigned to receive SRP + OHI treatment immediately and twenty-four only receive OHI and the delayed SRP treatment. Additionally, we divided participants into two stratifications according to initial HbA1c levels. The HbA1c values, proportion of peripheral CD4 + and CD8 + T-lymphocytes, CD4+/CD8 + ratio, and periodontal parameters: plaque index (PI), percentage of bleeding on probing (BOP%), pocket depth (PD) and clinical attachment level (CAL) were measured at baseline, 3 and 6 months.
resultsForty-eight participants completed the course of our study. At 6-month follow-up, the HbA1c reduction of SRP + OHI group is 0.22 ± 1.12%, greater than 0.07 ± 0.83% of OHI group(P = 0.592). When HbA1c ≥ 7.5%, the HbA1c reduction of SRP + OHI group is 0.74 ± 1.68%, comparing to 0.43 ± 0.91% of OHI group(P = 0.627); when HbA1c < 7.5%, the reductions were - 0.09 ± 0.39 and - 0.17 ± 0.70 respectively(P = 0.716). Both groups showed a slight decrease of peripheral CD4+/CD8 + ratio at 6-month revaluation. An 0.12 ± 0.08 increase of CD4+/CD8 + ratio was observed in SRP + OHI group when HbA1c ≥ 7.5%, which was significantly different to the conrol group(P = 0.040). As to periodontal parameters, PI, BOP% and PD were significantly improved after treatment, while the intergroup analysis in HbA1c ≥ 7.5% group showed no significant reduction of the PI and BOP% s at 6-months.
conclusionParticipants under hyperglycemia (HbA1c ≥ 7.5%) and stage III-IV periodontitis exhibited higher sensitivity of HbA1c level to SRP treatment. When HbA1c ≥ 7.5%, The peripheral CD4+/CD8 + ratio showed a slight increase in the intervention group while only reduction was found in other groups. And the peripheral CD4+/CD8 + ratio of SRP + OHI group in the HbA1c ≥ 7.5% stratification showed a significant increase while other subgroups all present a subtle decrease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.